MiyaresM. Comment: Pulmonary embolism after early change from rivaroxaban to aspirin following total knee replacement in an obese patient. Ann Pharmacother. 2015;49:851-852
2.
DenetclawTHWangPKWongGNguyenS. Pulmonary embolism after early change from rivaroxaban to aspirin following total knee replacement in an obese patient. Ann Pharmacother. 2015;49:851-852.
3.
KubitzaDBeckaMZuehlsdorfMMueckW. Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban of rivaroxaban. Errata. J Clin Pharmacol. 2008;48:1366-1368.
4.
Allman-FarinelliMA. Obesity and venous thrombosis: a review. Semin Thromb Hemost. 2011;37:903-907. doi:10.1055/s-0031-1297369.
5.
TurpieAGLassenMRErikssonBI. Rivaroxaban for the prevention of venous thrombosis after hip or knee arthroplasty: pooled analysis of 4 studies. Thromb Haemost. 2011;105:444-453. doi:10.1160/TH10-09-0601.
6.
CockcroftDWGaultMH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41.
7.
AdaneEDHeraldMKouraF. Pharmacokinetics of vancomycin in extremely obese patients with suspected or confirmed Staphylococcus aureus infections. Pharmacotherapy. 2015;35:127-139. doi:10.1002/phar.1531.
